International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Key facts

Sponsor

Institute of Cancer Research, United Kingdom

Principal Investigator

Steve Nicholson

Mid and South Essex NHS Foundation Trust

Intervention

ILND - Inguinal Lymph Node Dissection(procedure)

Enrollment

200 enrolled

Eligibility

18 years · MALE

Timeline

2017 – 2027

Study locations (17)

• Los Angeles County-USC Medical Center, Los Angeles, California, United States
• USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
• Moffitt Cancer Center, Tampa, Florida, United States
• Grady Health System, Atlanta, Georgia, United States
• Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
• University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
• Mayo Clinic, Rochester, Minnesota, United States
• Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
• University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
• Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
• University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
• Velindre NHS Trust, Cardiff, United Kingdom
• University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
• The Royal Marsden NHS Foundation Trust, London, United Kingdom
• St George's Hospital NHS Foundation Trust, London, United Kingdom
• +2 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI) · ECOG-ACRIN Cancer Research Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the penis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06666634
  Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy
  The Netherlands Cancer Institute
• RECRUITINGPHASE2NCT05526989
  Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
  H. Lee Moffitt Cancer Center and Research Institute

See all trials for Squamous cell carcinoma of the penis →